Pharmaceuticals Latin America

Latin America Novel Antibiotics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Latin America Novel Antibiotics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Infection, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Latin America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $352.0 Mn Placeholder estimate
Estimate 2025 $372.8 Mn 4.5% of the global market
Projected 2034 $624.5 Mn 67.5% Adds $251.7 Mn over 9 forecast years
CAGR 2025–2034 5.9% Faster than 15% of 180 Pharmaceuticals markets here
Key players 5
  • Latin America is 4.51% of the global market.
  • Among regions, the largest is North America at $4.41 Bn.
  • Fastest growing: Africa at 6.5% a year.
  • Latin America ranks 4th of 6 by size among regions.

Market size projection

Latin America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$251.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Novel Antibiotics Market market size by year, Latin America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $352.0 Mn — —
2025 (base) $372.8 Mn +$20.8 Mn —
2026 (forecast) $394.8 Mn +$22.0 Mn +5.9%
2027 (forecast) $418.1 Mn +$23.3 Mn +12.1%
2028 (forecast) $442.7 Mn +$24.7 Mn +18.8%
2029 (forecast) $468.9 Mn +$26.1 Mn +25.8%
2030 (forecast) $496.5 Mn +$27.7 Mn +33.2%
2031 (forecast) $525.8 Mn +$29.3 Mn +41.1%
2032 (forecast) $556.8 Mn +$31.0 Mn +49.4%
2033 (forecast) $589.7 Mn +$32.9 Mn +58.2%
2034 (forecast) $624.5 Mn +$34.8 Mn +67.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Latin America Novel Antibiotics Market Analysis at a glance
Market size, 2025$372.8 Mn placeholder estimate
Forecast, 2034$624.5 Mn placeholder estimate
Growth (CAGR), 2025–20345.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, infection and end user (see all)
Key playersPfizer Inc., Shionogi, Merck & Co., Inc., Innoviva Specialty Therapeutics, Venatorx Pharmaceuticals (see all)
Active clinical trials3 in Latin AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Latin America Novel Antibiotics Market Analysis Executive Summary

Novel antibiotics are new antibacterial drugs designed to treat infections caused by bacteria resistant to existing medicines.

Key segments of the novel Antibiotics market include drug class (Beta-Lactam Combinations, Novel Classes and Antibody Therapies) and infection (Gram-Negative, Gram-Positive and C. difficile).

Bar chart: Latin America Novel Antibiotics market size, 2024–2034, placeholder estimates. $352.0 Mn in 2024, $372.8 Mn in 2025 and $624.5 Mn in 2034, 5.9% CAGR.
Latin America Novel Antibiotics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Latin America Novel Antibiotics Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the novel Antibiotics market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the novel Antibiotics market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the novel Antibiotics market.

Competitive Landscape for Novel Antibiotics Market in Latin America

The novel Antibiotics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Novel Antibiotics Market in Latin America

Novel Antibiotics in Latin America: rules, payment and research

In some of the countries we cover here, medicines are approved by ANVISA (Brazil)⁠[1], ARCSA (Ecuador)⁠[2], COFEPRIS (Mexico)⁠[3], ANMAT (Argentina)⁠[4], INVIMA (Colombia)⁠[5] and ISP (Chile)⁠[6]. How care is paid for in some of these countries: the SUS (Brazil)⁠[7]; public care and IESS (Ecuador)⁠[8]; IMSS, ISSSTE and IMSS-Bienestar (Mexico)⁠[9]; public care, obras sociales and prepaid plans (Argentina)⁠[10]; social health insurance (EPS) (Colombia)⁠[11]; and FONASA and ISAPREs (Chile)⁠[12]. ClinicalTrials.gov lists 3 studies on Novel Antibiotics that are recruiting, active or about to start in Latin America.⁠[13]

[1] ANVISA. Checked 14 Nov 2026.

[2] ARCSA. Checked 14 Nov 2026.

[3] COFEPRIS. Checked 14 Nov 2026.

[4] ANMAT. Checked 19 Nov 2026.

[5] INVIMA. Checked 19 Nov 2026.

[6] Institute of Public Health of Chile (ISP). Checked 19 Nov 2026.

[7] CONITEC. Checked 14 Nov 2026.

[8] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.

[9] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.

[10] Superintendence of Health Services (SSSalud). Checked 19 Nov 2026.

[11] Ministry of Health and Social Protection. Checked 19 Nov 2026.

[12] FONASA. Checked 19 Nov 2026.

[13] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for novel Antibiotics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Latin America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Novel Antibiotics right now, from free public sources.

Clinical trials

3 active trials in Brazil, Mexico, Argentina, Colombia, Chile, Ecuador and Haiti

Recruiting, about to start, or running now. Counted across the 7 countries we report on in Latin America.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Novel Antibiotics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Novel Antibiotics market in Latin America?
Placeholder estimate: about $372.8 Mn in 2025, rising to about $624.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Novel Antibiotics market in Latin America growing?
Placeholder estimate: about 5.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Novel Antibiotics market report cover?
The report splits the market by drug class (Beta-Lactam Combinations, Novel Classes, Antibody Therapies, Phage Therapy), infection (Gram-Negative, Gram-Positive, C. difficile, Tuberculosis) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Novel Antibiotics market?
Key players include Pfizer Inc., Shionogi, Merck & Co., Inc., Innoviva Specialty Therapeutics and Venatorx Pharmaceuticals.
What is driving the Novel Antibiotics market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the novel Antibiotics market.
How many clinical trials on Novel Antibiotics are running in Latin America?
3 studies are recruiting, active or about to start in Latin America, counted across the 7 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.
How much research is published on Novel Antibiotics?
PubMed lists 914 papers on Novel Antibiotics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Latin America

See all

Related on antibiotics and infectious diseases

See the topic